Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab

The incorporation of rituximab, a chimeric anti-CD20 monoclonal antibody, into the therapeutic armamentarium for patients with follicular lymphoma (FL) has significantly improved treatment outcome for such patients. Despite the almost universal application of this therapy, however, its exact mechani...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hilchey, Shannon P., Hyrien, Ollivier, Mosmann, Tim R., Livingstone, Alexandra M., Friedberg, Jonathan W., Young, Faith, Fisher, Richard I., Kelleher, Raymond J., Bankert, Richard B., Bernstein, Steven H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2009
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2670795/
https://ncbi.nlm.nih.gov/pubmed/19196657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-10-185280
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak